Procaps Group, S.A ROE 2020-2023 | PROCF
Current and historical return on equity (ROE) values for Procaps Group, S.A (PROCF) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Procaps Group, S.A ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2023-09-30 |
$0.05B |
$0.04B |
284.93% |
| 2023-06-30 |
$0.07B |
$0.03B |
1116.67% |
| 2023-03-31 |
$0.03B |
$0.01B |
-347.37% |
| 2022-12-31 |
$0.04B |
$-0.00B |
-266.67% |
| 2022-09-30 |
$0.06B |
$-0.01B |
-242.42% |
| 2022-06-30 |
$-0.07B |
$-0.03B |
569.23% |
| 2022-03-31 |
$-0.07B |
$-0.02B |
533.33% |
| 2021-12-31 |
$-0.10B |
$-0.04B |
748.15% |
| 2021-09-30 |
$-0.14B |
$0.04B |
199.26% |
| 2021-06-30 |
$-0.03B |
$-0.03B |
33.11% |
| 2021-03-31 |
$-0.03B |
$-0.02B |
41.79% |
| 2020-12-31 |
$-0.01B |
$-0.26B |
15.00% |
| 2020-09-30 |
$-0.01B |
$0.01B |
-100.00% |
| 2019-12-31 |
$-0.00B |
$0.01B |
-160.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.125B |
$0.410B |
|
Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high-potency clinical solutions. Procaps Group, formerly known as Union Acquisition Corp. II, is based in BARRANQUILLA, Colombia.
|
